Age-related Macular Degeneration Market Size & Forecast 2034
The age-related macular degeneration (AMD) market was valued at USD 10.46 billion in 2024, driven primarily by the increasing prevalence of vision loss in the elderly population. AMD is one of the leading causes of irreversible blindness in individuals aged 60 and above. With growing awareness, early diagnosis, and advancements in treatment technologies, the AMD market is on a robust upward trajectory. According to Expert Market Research, the industry is expected to expand at a CAGR of 9.70% during the forecast period from 2025 to 2034, potentially reaching a market value of USD 26.40 billion by 2034. Factors such as the introduction of novel biologics, improved drug delivery systems, and expanded access to healthcare services are supporting this growth trend.
The rising burden of eye disorders, especially in developed countries, combined with the increasing adoption of precision medicine, is fueling investments in ophthalmology. Pharmaceutical companies are focusing on innovating drugs that can slow disease progression and improve patients' quality of life. Moreover, government programs aimed at elderly care and visual health screening are enhancing the demand for timely and effective AMD treatments.
Age-Related Macular Degeneration Market Share
The AMD market shows a notable concentration of market share among a few key pharmaceutical players, especially in the wet AMD segment. Wet AMD, although less common than dry AMD, contributes significantly to revenue due to the cost-intensive nature of its treatment. Anti-VEGF (vascular endothelial growth factor) therapies dominate the wet AMD market and are frequently prescribed due to their proven efficacy in slowing down vision loss.
Lucentis and Eylea have captured a substantial portion of the treatment market, with Avastin also being widely used off-label. Among regions, North America holds the largest share, supported by high diagnosis rates, widespread use of anti-VEGF agents, and a strong reimbursement framework. Europe follows closely, benefitting from public health initiatives and a growing geriatric demographic.
In contrast, emerging markets in Asia Pacific and Latin America are experiencing rising demand due to improvements in healthcare infrastructure, increased screening programs, and growing awareness among the aging population. As these regions continue to invest in healthcare access and affordability, they are expected to significantly contribute to global market growth in the coming years.
Age-Related Macular Degeneration Market Growth & Trends
Key Growth Drivers
-
Demographic Shifts: Aging populations globally are leading to a higher incidence of age-related diseases, including AMD. By 2050, it is estimated that over 1.3 billion people will be over the age of 60, directly correlating with an increased patient base for AMD therapies.
-
Innovations in Imaging and Diagnosis: Tools like optical coherence tomography (OCT) and fluorescein angiography are enhancing early detection capabilities, enabling better disease management.
-
Expansion of Anti-VEGF Therapies: Anti-VEGF drugs have become the gold standard for wet AMD treatment, and their expanded indications and improved formulations are making therapies more effective and patient-friendly.
-
Public Health Awareness: Campaigns emphasizing regular eye exams, particularly among the elderly, are boosting early-stage diagnosis and treatment rates.
Emerging Trends
-
Extended-Release and Long-Acting Formulations: Pharmaceutical companies are developing drugs that require fewer injections, reducing the treatment burden on patients and improving compliance.
-
Gene Therapy and Stem Cell Research: These novel therapeutic areas are gaining interest, especially in treating advanced stages of AMD where traditional therapies are less effective. Several companies are already in early-phase trials.
-
Artificial Intelligence and Teleophthalmology: AI is being used to assist in the diagnosis and progression monitoring of AMD, especially in remote or underserved areas. Telemedicine is expanding access to care for elderly patients who may have mobility limitations.
Age-Related Macular Degeneration Market Case Studies & News
Several recent developments are shaping the trajectory of the AMD treatment landscape:
-
Roche/Genentech launched Vabysmo, a first-in-class bispecific antibody that targets both VEGF-A and Angiopoietin-2 (Ang-2), offering extended dosing intervals compared to traditional anti-VEGF agents.
-
Regeneron Pharmaceuticals is working on Eylea HD, a higher-dose formulation designed to extend the duration between injections while maintaining efficacy.
-
In 2023, Apellis Pharmaceuticals made headlines with the FDA approval of Syfovre, the first treatment for geographic atrophy, a late-stage form of dry AMD. This marked a significant milestone, providing an option for patients previously without any FDA-approved treatment.
-
Novartis AG continues to invest heavily in gene therapy approaches and recently entered into multiple strategic partnerships to enhance its ophthalmology pipeline.
These case studies underline the industrys commitment to developing long-acting, minimally invasive, and disease-modifying therapies for both wet and dry AMD.
Age-Related Macular Degeneration Market Analysis
The competitive landscape of the AMD market is characterized by the presence of a few dominant players with a strong focus on research and innovation. Market dynamics are influenced by factors such as patent expirations, biosimilar competition, regulatory pathways, and payer reimbursement policies. Strategic collaborations and M&A activities are common as companies strive to diversify their treatment portfolios and strengthen their market presence.
North America is expected to retain its dominance over the forecast period, backed by increasing healthcare expenditure and technological innovation. Meanwhile, Asia Pacific is projected to grow at the fastest rate, driven by a combination of population aging, healthcare reforms, and rising disposable income in countries like China and India.
Regulatory Influence: Agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are providing accelerated approvals for breakthrough therapies and expanding the use of conditional approvals for emerging treatments. These regulatory shifts are expediting the availability of novel AMD therapies in the market.
Market Segmentation
By Product Type:
-
Wet AMD
-
Dry AMD
By Drug:
-
Lucentis
-
Eylea
-
Avastin
-
Others
By Route of Administration:
-
Intravenous
-
Intravitreal
By Region:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East and Africa
Market Key Players
-
Bayer AG
-
F. Hoffmann-La Roche Ltd.
-
Novartis AG
-
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN)
-
Others
With continued investment in R&D and a growing base of patients seeking vision-preserving therapies, the AMD market is expected to remain a key focus within the ophthalmology segment. Ongoing advancements and strategic collaborations among pharmaceutical leaders are likely to create a more competitive and innovative market landscape in the coming decade.
See More Reports
About Us:
Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.
Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.
Media Contact:
Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com
